Acrobiosystems Co

Acrobiosystems Co Current Ratio

The Current Ratio of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 3.42. In the previous year, Current Ratio was 2.17 — a change of 57.98% (higher).

Current Ratio

3.42

YoY

57.98%

Last updated:

Current Ratio of Acrobiosystems Co is 2025 3.42 . Current Ratio of Acrobiosystems Co was 2024 2.17 . It decreases by 57.98% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Current Ratio of Acrobiosystems Co is 3.42 in 2025.

Current Ratio of Acrobiosystems Co changed from 2.17 to 3.42, representing a 57.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Ratio Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

The Current Ratio measures a company's ability to pay short-term obligations. A ratio above 1 indicates that current assets exceed current liabilities.

Current Ratio = Current Assets / Current Liabilities

A 'good' varies by industry and company stage. On Eulerpool, you can compare Current Ratio's Acrobiosystems Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co